News Search Results
Nov 17, 2025, 08:05 ET Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology
Calif., Nov. 17, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced a peer-reviewed publication in the Journal of Hematology & Oncology
More news about: Rigel Pharmaceuticals, Inc.
Nov 17, 2025, 08:01 ET TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
specializing in strategic support and portfolio management for early-stage pharmaceutical development. Through JMi ONConsulting, he has advised leading biotechnology companies in Europe and the U.S. on oncology R&D, preclinical and clinical strategy, and business development initiatives. He also co-founded
More news about: TransCode Therapeutics, Inc.
Nov 17, 2025, 07:00 ET NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute
NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Prof.
More news about: NewcelX Ltd.
Nov 17, 2025, 07:00 ET Nanoscope Therapeutics Featured in Multiple Presentations at Advanced Therapies USA 2025
Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment
More news about: Nanoscope Therapeutics
Nov 17, 2025, 07:00 ET Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab
one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Nov 17, 2025, 05:36 ET Stars of Science: Celebrating 17 Seasons of Innovators Driving the Region's Scientific Future
that estimates Vitamin D levels in the body and helps prevent mental health symptoms, won public voting and impressed judges for its fusion of biotechnology with emotional well-being. "Stars of Science transformed my journey - I turned pain into hope
More news about: Stars of Science
Nov 15, 2025, 11:00 ET BrainXell Showcases Pioneering iPSC Research and Promising In Vivo Data for BXT-110 for Parkinson's Disease at the 2025 Society for Neuroscience Annual Meeting
neurodegenerative disorders. Dr. Su-Chun Zhang, BrainXell Founder and Advising CSO, states, "BrainXell is at the forefront of the biotechnology industry, engineering novel cellular platforms for biomedical discovery and pharmaceutical development, as well as developing personalized regenerative
More news about: BrainXell, Inc
Nov 14, 2025, 11:10 ET OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion
About Vaximm AG Vaximm AG is a privately held Swiss-German biotechnology company and a subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH). Vaximm's proprietary oral T-cell vaccination platform harnesses live, attenuated
More news about: OSR Holdings
Nov 14, 2025, 10:30 ET AI in Biotechnology Market worth $22,716.5 million by 2035 with 18.5% CAGR | MarketsandMarkets™.
end-to-end solutions segment accounted for the largest share of the AI in biotechnology market, driven by the rising demand for integrated platforms that combine data management, analytics, and automation across the entire biotechnology workflow. These solutions enable seamless collaboration between research
More news about: MarketsandMarkets
Nov 14, 2025, 09:26 ET Curis to Present at Upcoming 30th Annual SNO Meeting
LEXINGTON, Mass., Nov. 14, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that Curis will
More news about: Curis, Inc.
Nov 14, 2025, 08:53 ET SAS Clinical Acceleration debuts to modernize clinical trials and accelerate time to market
N.C., Nov. 14, 2025 /PRNewswire/ -- In today's rapidly evolving health care landscape, pharmaceutical and biotechnology companies face mounting pressure to accelerate drug development while maintaining rigorous compliance with global regulatory standards. And the
More news about: SAS
Nov 14, 2025, 08:00 ET ETHZilla Reports Third Quarter 2025 Financial Results
: Successfully resolved all outstanding litigation against the legacy company, 180 Life Sciences, and divested the legacy biotechnology assets. The Company continues to retain the previously acquired iGaming assets until the physical assets associated with the tokenization
More news about: ETHZilla Corporation
Nov 14, 2025, 07:00 ET Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S., the First Product from its Proprietary Long-Acting Injectable Platform PrecisionSphere™
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Limited
Nov 14, 2025, 06:24 ET A KHB apresenta o FOCUS PEGASUS MF200 aprimorado -- redefinindo a eficiência em diagnósticos veterinários
XI'AN, China, 14 de novembro de 2025 /PRNewswire/ -- A Guangzhou Focus Biotechnology Co., Ltd., subsidiária do KHB Group e inovadora em soluções de testes veterinários no local de atendimento (POCT), apresenta o aprimorado Analisador
More news about: Shanghai Kehua Bio-engineering Co., Ltd.
Nov 14, 2025, 06:22 ET KHB presenta el FOCUS PEGASUS MF200 mejorado: una redefinición de la eficacia en el diagnóstico veterinario
XI'AN, China, 14 de noviembre de 2025 /PRNewswire/ -- Guangzhou Focus Biotechnology Co., Ltd., una filial de KHB Group e innovadora en soluciones de pruebas veterinarias en el punto de atención (POCT), presenta el analizador veterinario
More news about: Shanghai Kehua Bio-engineering Co., Ltd.
Nov 14, 2025, 06:19 ET KHB präsentiert verbesserten FOCUS PEGASUS MF200 - die Neudefinition von Effizienz in der Veterinärdiagnostik
XI'AN, China, 14. November 2025 /PRNewswire/ -- Guangzhou Focus Biotechnology Co., Ltd, eine Tochtergesellschaft der KHB Group und ein Innovator im Bereich der veterinärmedizinischen Point-of-Care-Tests (POCT), präsentiert
More news about: Shanghai Kehua Bio-engineering Co., Ltd.
Nov 14, 2025, 06:15 ET KHB présente le FOCUS PEGASUS MF200 amélioré - Redéfinir l'efficacité du diagnostic vétérinaire
XI'AN, Chine, 14 novembre 2025 14 novembre 2025 /PRNewswire/ -- Guangzhou Focus Biotechnology Co. Ltd, filiale du groupe KHB et innovateur en matière de solutions de tests vétérinaires sur le lieu de soins (POCT), présente l'analyseur vétérinaire
More news about: Shanghai Kehua Bio-engineering Co., Ltd.
Nov 14, 2025, 03:00 ET Medicxi Announces €500 Million Fund V
life sciences venture capital firm, today announced the closing of Medicxi V, a €500 million fund dedicated to building and backing innovative biotechnology companies with clear product visions to transform patient care. The oversubscribed fund closed with strong support from existing limited partners
More news about: Medicxi
Nov 14, 2025, 03:00 ET PRISM BioLab Achieved Initial Milestone and Receives the Milestone Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd.
and enhancement of corporate value. About PRISM BioLab PRISM BioLab is a discovery and development biotechnology company utilizing proprietary PepMetics® technology to discover orally available small molecule inhibitors of protein-protein interaction (PPI)
More news about: PRISM BioLab Co., Ltd.
Nov 13, 2025, 22:30 ET Laboratory Centrifuges Market worth $1.86 billion by 2030 with 2.8% CAGR | MarketsandMarkets™
regional market, mainly due to the presence of emerging economies like China and India and the increasing R&D investments by pharmaceutical and biotechnology companies in this region. Download PDF Brochure:
More news about: MarketsandMarkets
Nov 13, 2025, 21:10 ET KHB presenta el FOCUS PEGASUS MF200 mejorado: redefiniendo la eficiencia en el diagnóstico veterinario
XI'AN, China, 14 de noviembre de 2025 /PRNewswire/ -- Guangzhou Focus Biotechnology Co., Ltd., filial de KHB Group e innovadora en soluciones de diagnóstico veterinario en el punto de atención (POCT), presenta el analizador veterinario
More news about: Shanghai Kehua Bio-engineering Co., Ltd.
Nov 13, 2025, 20:27 ET KHB、改良型FOCUS PEGASUS MF200を披露 -- 獣医診断の効率性を再定義
中国西安、2025年11月14日 /PRNewswire/ -- KHBグループの子会社であり、獣医向けポイントオブケア（POCT）ソリューションのイノベーターであるGuangzhou Focus Biotechnology Co., Ltd.は、改良型FOCUS PEGASUS MF200 自動多機能獣医用アナライザーを発表した。次世代システムとして、獣医診断における効率性、信頼性、アクセス性を再定義する。
More news about: Shanghai Kehua Bio-engineering Co., Ltd.
Nov 13, 2025, 20:27 ET KHB, 업그레이드된 'FOCUS PEGASUS MF200' 공개 -- 수의 진단 효율성 재정의
시안, 중국 2025년 11월 14일 /PRNewswire/ -- KHB 그룹의 자회사이자 수의 현장 진단(POCT) 솔루션 혁신 기업인 광저우 포커스 바이오테크놀로지(Guangzhou Focus Biotechnology Co., Ltd.)가 자동 다기능 수의학 분석기 'FOCUS PEGASUS MF200' 업그레이드 버전을 선보였다. MF200은 수의 진단 분야에서 효율성, 신뢰성, 접근성을 새롭게 정의하는 차세대 시스템이다.
More news about: Shanghai Kehua Bio-engineering Co., Ltd.
Nov 13, 2025, 16:05 ET Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results
About Kodiak Sciences Inc. Kodiak Sciences (Nasdaq: KOD) is a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design
More news about: Kodiak Sciences Inc.
Nov 13, 2025, 15:38 ET General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutics Using OmniTAC™ Platform
SAN FRANCISCO, Nov. 12, 2025 /PRNewswire/ -- General Proximity, a biotechnology company discovering and developing the next generation of induced proximity medicines, today announced a strategic multi-target collaboration with
More news about: General Proximity